Oruka Therapeutics Stock Slides Despite Positive Clinical Trial Data

Oruka Therapeutics (ORKA) stock fell 2.5% in pre-open trading as investors reacted to the release of positive, yet largely expected, clinical trial data, creating a classic "sell the news" scenario. The decline comes despite the company reporting strong efficacy for its drug candidate, ORKA-001, suggesting the positive outcome was already priced into the stock following a significant rally over the past year.

Strong Data Meets High Expectations

Oruka announced updated Week 28 data from its EVERLAST-A Phase 2a trial, which showed continued improvement in patient outcomes. The company reported that:

• 71.4% of patients achieved PASI 100, indicating complete skin clearance, an increase from 63.5% at Week 16.
• 87.3% of patients reached a PASI 90 response rate.
• 84.1% of patients achieved an IGA 0/1 response.

According to the company, these deepening responses were observed without any additional dosing after Week 4. While Oruka's Chief Medical Officer highlighted the data as pointing to the drug's "incredible potential," the market's muted response indicates these strong results were anticipated by investors. The stock had previously surged from a 52-week low of $14.89 to a high of $115.515, leaving little room for further upside surprise.

Insider Sale and Market Headwinds

Ad

Adding to investor caution was a recent insider transaction. Paul T. Quinlan, the company's General Counsel, sold 10,000 shares on September 21 for approximately $936,417. The sale was executed under a pre-established Rule 10b5-1 trading plan dated May 15, 2026. While such pre-planned sales are routine, the timing—just two days before a major data release—may have amplified cautious sentiment.

A weaker broader market provided an unfavorable backdrop. The S&P 500, Dow Jones, and Nasdaq all edged lower in pre-market trading amid uncertainty surrounding upcoming speeches from Federal Reserve officials. This macroeconomic pressure, combined with the stock's elevated valuation, contributed to the conditions for a pullback.

Looking Ahead

Investors are now looking toward future catalysts for Oruka Therapeutics. The company plans to share Week 52 efficacy data for all patients in December 2026. Additionally, 16-week data from the ongoing EVERLAST-B Phase 2b trial is expected in the fourth quarter of 2026.